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Cerebral malaria (CM) is a severe complicated form of
malaria, resulting in an overwhelming inflammatory
response in the brain due to infection from Plasmo-
dium-falciparum[1]. Only a fraction of malaria infected
individuals develop CM and it has been shown that
both genetic and non-genetic factors determine CM sus-
ceptibility [2]. Variants in Interferon alpha receptor-1
(IFNAR1) have been associated with protection from
CM in humans [3] and in susceptibility to severe forms
of malaria, such as CM. As in humans, susceptibility of
mice to CM is determined by genetic factors (unpub-
lished data, Sambo et al).
Type-I Interferon, a/b (IFN-I), plays a key role in reg-
ulating the immune response through release of pro-
and anti-inflammatory cytokines and stimulating antigen
presentation and cellular cytotoxicity. Its expression has
been found to be up regulated upon infection with
viruses and bacteria, and can illicit protective or disease-
aggravating effects [4]. From this knowledge we
hypothesize that IFNAR1 is a determinant of the inflam-
matory response that leads to development of Experi-
mental cerebral malaria (ECM).
Ifnar1-/- mice were infected with Plasmodium berghei
ANKA (P.berghei ANKA) and assessed for survival and
development of ECM. 70% of mice did not develop ECM
and died 28-30 days later from anemia and hyper-parasi-
temia. Ifnar1-/- mice do not show a decrease in parasite
burden, and display mild blood brain barrier breakage.
We are currently investigating brain vasculature and
infiltration of inflammatory molecules within these mice
and are conducting transfer experiments using Ifnar1-/-
and Rag2-/-mice with the aim of defining the role
of IFNAR1 in development of ECM upon infection with
P.berghei ANKA, and determiningw h e r ea n dh o wt h i s
protection is inflicted.
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